Michael Verneris
Concepts (698)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 103 | 2025 | 704 | 14.090 |
Why?
| | Graft vs Host Disease | 55 | 2025 | 283 | 7.490 |
Why?
| | Killer Cells, Natural | 52 | 2020 | 481 | 7.020 |
Why?
| | Transplantation Conditioning | 42 | 2021 | 193 | 5.280 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 37 | 2023 | 299 | 5.050 |
Why?
| | Cord Blood Stem Cell Transplantation | 33 | 2021 | 103 | 4.740 |
Why?
| | Hematologic Neoplasms | 28 | 2024 | 170 | 3.110 |
Why?
| | Transplantation, Homologous | 46 | 2025 | 416 | 2.850 |
Why?
| | Leukemia, Myeloid, Acute | 29 | 2025 | 702 | 2.830 |
Why?
| | Unrelated Donors | 21 | 2021 | 39 | 2.610 |
Why?
| | Leukemia | 20 | 2023 | 246 | 2.520 |
Why?
| | Fetal Blood | 15 | 2017 | 325 | 2.490 |
Why?
| | Hematopoietic Stem Cells | 10 | 2025 | 432 | 2.360 |
Why?
| | Immunity, Innate | 8 | 2025 | 844 | 2.290 |
Why?
| | Immunotherapy, Adoptive | 27 | 2026 | 356 | 2.050 |
Why?
| | Myelodysplastic Syndromes | 16 | 2020 | 170 | 1.780 |
Why?
| | Lymphocytes | 7 | 2025 | 379 | 1.700 |
Why?
| | Antibodies, Bispecific | 5 | 2021 | 70 | 1.660 |
Why?
| | T-Lymphocytes | 17 | 2026 | 2012 | 1.560 |
Why?
| | Cell Differentiation | 13 | 2022 | 1982 | 1.480 |
Why?
| | Neoplasm, Residual | 7 | 2021 | 143 | 1.460 |
Why?
| | Receptors, Antigen, T-Cell | 15 | 2026 | 677 | 1.410 |
Why?
| | Recurrence | 33 | 2026 | 1133 | 1.340 |
Why?
| | Bone Marrow Transplantation | 12 | 2017 | 301 | 1.310 |
Why?
| | Haplotypes | 4 | 2021 | 506 | 1.310 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2026 | 92 | 1.290 |
Why?
| | CD56 Antigen | 9 | 2020 | 34 | 1.280 |
Why?
| | Child | 97 | 2026 | 22693 | 1.260 |
Why?
| | Disease-Free Survival | 29 | 2021 | 778 | 1.260 |
Why?
| | Cytomegalovirus Infections | 8 | 2024 | 206 | 1.230 |
Why?
| | Humans | 229 | 2026 | 146342 | 1.210 |
Why?
| | Cell- and Tissue-Based Therapy | 4 | 2024 | 82 | 1.140 |
Why?
| | Child, Preschool | 66 | 2026 | 11913 | 1.110 |
Why?
| | Adolescent | 92 | 2026 | 22557 | 1.100 |
Why?
| | HLA Antigens | 9 | 2017 | 241 | 1.100 |
Why?
| | Interleukins | 4 | 2015 | 248 | 1.100 |
Why?
| | Antineoplastic Agents | 13 | 2021 | 2219 | 1.060 |
Why?
| | Young Adult | 69 | 2025 | 14330 | 1.050 |
Why?
| | Antigens, CD19 | 12 | 2026 | 137 | 1.040 |
Why?
| | Receptors, IgG | 8 | 2019 | 77 | 1.040 |
Why?
| | Immunotherapy | 10 | 2024 | 671 | 1.020 |
Why?
| | Lymphoid Tissue | 3 | 2021 | 82 | 1.000 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2019 | 127 | 0.990 |
Why?
| | Graft Survival | 9 | 2018 | 523 | 0.950 |
Why?
| | Stem Cell Transplantation | 4 | 2025 | 190 | 0.940 |
Why?
| | Cytomegalovirus | 9 | 2024 | 172 | 0.940 |
Why?
| | Bone Neoplasms | 5 | 2025 | 272 | 0.940 |
Why?
| | Infant | 51 | 2026 | 10114 | 0.930 |
Why?
| | Virus Activation | 5 | 2024 | 97 | 0.930 |
Why?
| | Interleukin-9 | 1 | 2025 | 12 | 0.920 |
Why?
| | Cytokines | 10 | 2018 | 2081 | 0.880 |
Why?
| | B7 Antigens | 2 | 2024 | 18 | 0.880 |
Why?
| | Interleukin-8 | 2 | 2024 | 268 | 0.870 |
Why?
| | Receptors, KIR | 9 | 2015 | 123 | 0.860 |
Why?
| | Adult | 96 | 2026 | 41087 | 0.860 |
Why?
| | Survival Analysis | 23 | 2020 | 1378 | 0.850 |
Why?
| | Histocompatibility Testing | 10 | 2018 | 124 | 0.850 |
Why?
| | Cryopreservation | 2 | 2017 | 115 | 0.840 |
Why?
| | Whole-Body Irradiation | 8 | 2018 | 73 | 0.840 |
Why?
| | Antigens, CD | 6 | 2019 | 560 | 0.830 |
Why?
| | Male | 118 | 2026 | 73396 | 0.820 |
Why?
| | Female | 122 | 2026 | 79499 | 0.800 |
Why?
| | Adoptive Transfer | 4 | 2017 | 197 | 0.800 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 78 | 0.790 |
Why?
| | Histocompatibility | 6 | 2019 | 20 | 0.790 |
Why?
| | Tissue Donors | 10 | 2024 | 425 | 0.790 |
Why?
| | Treatment Outcome | 45 | 2025 | 11821 | 0.780 |
Why?
| | Immune Reconstitution | 2 | 2025 | 10 | 0.770 |
Why?
| | Cellular Senescence | 1 | 2025 | 225 | 0.770 |
Why?
| | Sarcoma, Ewing | 4 | 2025 | 103 | 0.760 |
Why?
| | Graft vs Leukemia Effect | 3 | 2013 | 12 | 0.740 |
Why?
| | Hemangioblasts | 1 | 2022 | 4 | 0.730 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 3 | 2018 | 35 | 0.730 |
Why?
| | Lymphocyte Depletion | 5 | 2019 | 135 | 0.720 |
Why?
| | Middle Aged | 74 | 2026 | 36619 | 0.720 |
Why?
| | HLA-C Antigens | 3 | 2016 | 37 | 0.710 |
Why?
| | Receptors, Immunologic | 6 | 2016 | 210 | 0.690 |
Why?
| | Lymphoid Progenitor Cells | 2 | 2020 | 11 | 0.680 |
Why?
| | Interferon-gamma | 9 | 2014 | 781 | 0.660 |
Why?
| | CD48 Antigen | 1 | 2020 | 3 | 0.660 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 7 | 0.650 |
Why?
| | Transplantation, Autologous | 6 | 2025 | 306 | 0.650 |
Why?
| | Lymphoma, B-Cell | 5 | 2026 | 150 | 0.650 |
Why?
| | Bone Marrow | 9 | 2017 | 310 | 0.640 |
Why?
| | Receptors, Prolactin | 1 | 2020 | 6 | 0.630 |
Why?
| | Smad7 Protein | 1 | 2020 | 20 | 0.620 |
Why?
| | Leukemia, Myeloid | 2 | 2017 | 49 | 0.620 |
Why?
| | Lymphopoiesis | 1 | 2020 | 27 | 0.620 |
Why?
| | Burkitt Lymphoma | 4 | 2023 | 61 | 0.610 |
Why?
| | Prolactin | 1 | 2020 | 88 | 0.610 |
Why?
| | Monocytes | 3 | 2020 | 538 | 0.610 |
Why?
| | Transplantation Chimera | 2 | 2019 | 57 | 0.590 |
Why?
| | Interleukin-2 | 5 | 2019 | 434 | 0.580 |
Why?
| | Cells, Cultured | 15 | 2022 | 4118 | 0.580 |
Why?
| | GATA3 Transcription Factor | 1 | 2019 | 22 | 0.580 |
Why?
| | Cell Proliferation | 12 | 2019 | 2502 | 0.580 |
Why?
| | Crohn Disease | 1 | 2022 | 250 | 0.570 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 176 | 0.570 |
Why?
| | Interleukin-15 | 5 | 2019 | 96 | 0.570 |
Why?
| | Adipokines | 1 | 2018 | 56 | 0.540 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 352 | 0.540 |
Why?
| | Allografts | 13 | 2021 | 151 | 0.540 |
Why?
| | Mice | 27 | 2025 | 18297 | 0.530 |
Why?
| | Cell Lineage | 3 | 2020 | 377 | 0.530 |
Why?
| | Delayed Graft Function | 1 | 2018 | 56 | 0.530 |
Why?
| | Piperazines | 3 | 2009 | 368 | 0.530 |
Why?
| | Retrospective Studies | 38 | 2026 | 17438 | 0.530 |
Why?
| | Histocompatibility Antigens Class I | 4 | 2019 | 207 | 0.520 |
Why?
| | Survival Rate | 18 | 2020 | 2092 | 0.520 |
Why?
| | Aged | 49 | 2026 | 26432 | 0.520 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2599 | 0.510 |
Why?
| | Antigens, CD34 | 4 | 2022 | 89 | 0.500 |
Why?
| | Acute Disease | 17 | 2019 | 1038 | 0.490 |
Why?
| | Siblings | 7 | 2019 | 202 | 0.490 |
Why?
| | Stromal Cells | 4 | 2011 | 123 | 0.490 |
Why?
| | Pyrimidines | 3 | 2009 | 532 | 0.490 |
Why?
| | Prognosis | 17 | 2025 | 4351 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2025 | 931 | 0.480 |
Why?
| | Myeloid Progenitor Cells | 2 | 2020 | 16 | 0.480 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2015 | 415 | 0.480 |
Why?
| | Blood Donors | 4 | 2016 | 145 | 0.470 |
Why?
| | Cell Degranulation | 3 | 2013 | 40 | 0.470 |
Why?
| | Bone Marrow Cells | 3 | 2020 | 328 | 0.460 |
Why?
| | Lymphocyte Activation | 12 | 2016 | 1137 | 0.460 |
Why?
| | Time Factors | 17 | 2019 | 7109 | 0.450 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2015 | 5 | 0.450 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2015 | 8 | 0.450 |
Why?
| | Self Tolerance | 2 | 2013 | 27 | 0.450 |
Why?
| | Pulmonary Embolism | 2 | 2010 | 246 | 0.440 |
Why?
| | Up-Regulation | 3 | 2015 | 841 | 0.440 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2026 | 33 | 0.430 |
Why?
| | Neuroblastoma | 2 | 2025 | 177 | 0.420 |
Why?
| | Neoplasms | 10 | 2022 | 2954 | 0.420 |
Why?
| | Immunologic Memory | 5 | 2025 | 369 | 0.420 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 370 | 0.420 |
Why?
| | Receptors, Calcitriol | 1 | 2014 | 54 | 0.410 |
Why?
| | Calcitriol | 1 | 2014 | 59 | 0.410 |
Why?
| | Animals | 32 | 2025 | 38107 | 0.410 |
Why?
| | Recombinant Fusion Proteins | 5 | 2021 | 663 | 0.400 |
Why?
| | Mitochondria | 4 | 2021 | 997 | 0.400 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2009 | 128 | 0.390 |
Why?
| | Donor Selection | 4 | 2018 | 66 | 0.390 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2013 | 18 | 0.390 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 30 | 0.380 |
Why?
| | Single-Chain Antibodies | 1 | 2013 | 15 | 0.380 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2016 | 1150 | 0.380 |
Why?
| | Mycophenolic Acid | 3 | 2016 | 117 | 0.380 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 4 | 2015 | 9 | 0.380 |
Why?
| | Cell Line, Tumor | 11 | 2024 | 3545 | 0.380 |
Why?
| | Vitamins | 1 | 2014 | 183 | 0.380 |
Why?
| | Immunophenotyping | 8 | 2019 | 324 | 0.370 |
Why?
| | Cytotoxicity, Immunologic | 10 | 2016 | 224 | 0.360 |
Why?
| | Chromosome Aberrations | 1 | 2013 | 167 | 0.360 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2018 | 1160 | 0.360 |
Why?
| | Metabolic Syndrome | 1 | 2016 | 364 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 1998 | 0.350 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2011 | 15 | 0.350 |
Why?
| | Osteosarcoma | 2 | 2024 | 100 | 0.350 |
Why?
| | Lymphocyte Count | 4 | 2017 | 167 | 0.350 |
Why?
| | Remission Induction | 9 | 2018 | 308 | 0.340 |
Why?
| | Carcinoma | 1 | 2013 | 225 | 0.330 |
Why?
| | Immunosuppressive Agents | 4 | 2015 | 829 | 0.330 |
Why?
| | Cell Communication | 1 | 2013 | 327 | 0.320 |
Why?
| | Lymphocyte Subsets | 3 | 2021 | 79 | 0.320 |
Why?
| | Neutropenia | 2 | 2025 | 153 | 0.320 |
Why?
| | Graft vs Tumor Effect | 3 | 2017 | 8 | 0.320 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 3 | 2016 | 10 | 0.320 |
Why?
| | Salvage Therapy | 1 | 2011 | 166 | 0.310 |
Why?
| | Heparin | 1 | 2011 | 247 | 0.310 |
Why?
| | K562 Cells | 6 | 2014 | 93 | 0.310 |
Why?
| | Risk Factors | 21 | 2025 | 10921 | 0.300 |
Why?
| | Incidence | 8 | 2019 | 2936 | 0.300 |
Why?
| | Myeloablative Agonists | 5 | 2016 | 23 | 0.290 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 200 | 0.290 |
Why?
| | Body Mass Index | 1 | 2018 | 2458 | 0.290 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2024 | 930 | 0.280 |
Why?
| | Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.280 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2008 | 39 | 0.280 |
Why?
| | Cyclosporine | 3 | 2016 | 256 | 0.280 |
Why?
| | Philadelphia Chromosome | 1 | 2008 | 18 | 0.280 |
Why?
| | Influenza Vaccines | 2 | 2016 | 544 | 0.280 |
Why?
| | Infant, Newborn | 9 | 2019 | 6460 | 0.280 |
Why?
| | Hematopoiesis | 3 | 2020 | 195 | 0.270 |
Why?
| | Medical Oncology | 1 | 2011 | 345 | 0.270 |
Why?
| | Lymphocyte Transfusion | 3 | 2016 | 20 | 0.270 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2019 | 57 | 0.270 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 78 | 0.270 |
Why?
| | Epidermal Growth Factor | 3 | 2017 | 157 | 0.270 |
Why?
| | Natural Killer T-Cells | 1 | 2008 | 71 | 0.270 |
Why?
| | Antibodies | 5 | 2018 | 400 | 0.260 |
Why?
| | Cell Count | 3 | 2014 | 315 | 0.260 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 970 | 0.260 |
Why?
| | Polymorphism, Genetic | 3 | 2016 | 612 | 0.260 |
Why?
| | Chronic Disease | 6 | 2023 | 1827 | 0.260 |
Why?
| | Coculture Techniques | 5 | 2020 | 245 | 0.260 |
Why?
| | Follow-Up Studies | 9 | 2020 | 5439 | 0.250 |
Why?
| | GPI-Linked Proteins | 4 | 2019 | 81 | 0.250 |
Why?
| | Alleles | 4 | 2017 | 907 | 0.240 |
Why?
| | HLA-DP beta-Chains | 2 | 2017 | 88 | 0.240 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.240 |
Why?
| | Apoptosis | 7 | 2011 | 2439 | 0.230 |
Why?
| | Cell Separation | 3 | 2020 | 300 | 0.230 |
Why?
| | Peritoneal Dialysis | 1 | 2007 | 100 | 0.230 |
Why?
| | Hyperglycemia | 2 | 2020 | 384 | 0.230 |
Why?
| | CD57 Antigens | 3 | 2015 | 18 | 0.230 |
Why?
| | Heart Diseases | 1 | 2009 | 343 | 0.220 |
Why?
| | Neoplasms, Experimental | 2 | 2005 | 163 | 0.220 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 77 | 0.210 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 67 | 0.210 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2013 | 143 | 0.210 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 2 | 2023 | 27 | 0.210 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Blood Platelets | 3 | 2021 | 382 | 0.210 |
Why?
| | Chimerism | 2 | 2021 | 35 | 0.210 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2024 | 5 | 0.210 |
Why?
| | Probiotics | 1 | 2025 | 64 | 0.210 |
Why?
| | Diphtheria Toxin | 2 | 2015 | 61 | 0.210 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 444 | 0.210 |
Why?
| | Risk | 3 | 2018 | 920 | 0.200 |
Why?
| | Membrane Proteins | 8 | 2015 | 1130 | 0.200 |
Why?
| | Benzamides | 3 | 2009 | 226 | 0.200 |
Why?
| | Follistatin | 3 | 2019 | 11 | 0.200 |
Why?
| | Major Histocompatibility Complex | 2 | 2018 | 234 | 0.200 |
Why?
| | Cohort Studies | 12 | 2021 | 6077 | 0.190 |
Why?
| | Endoglin | 3 | 2019 | 19 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1064 | 0.190 |
Why?
| | Lymphoma | 3 | 2003 | 251 | 0.190 |
Why?
| | Receptors, Natural Killer Cell | 4 | 2014 | 16 | 0.190 |
Why?
| | Neutrophils | 4 | 2017 | 1133 | 0.190 |
Why?
| | Gastrointestinal Diseases | 1 | 2025 | 220 | 0.190 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1339 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 102 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 893 | 0.180 |
Why?
| | Flow Cytometry | 5 | 2020 | 1163 | 0.180 |
Why?
| | Mutation | 4 | 2019 | 4093 | 0.180 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2020 | 52 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 1 | 2009 | 983 | 0.180 |
Why?
| | Hodgkin Disease | 2 | 2001 | 173 | 0.180 |
Why?
| | Combined Modality Therapy | 6 | 2021 | 1271 | 0.180 |
Why?
| | Maximum Tolerated Dose | 3 | 2017 | 217 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1408 | 0.180 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2021 | 4 | 0.170 |
Why?
| | Sarcoma | 1 | 2024 | 209 | 0.170 |
Why?
| | Virus Diseases | 1 | 2024 | 219 | 0.170 |
Why?
| | Proteins | 4 | 2018 | 1022 | 0.170 |
Why?
| | Multivariate Analysis | 5 | 2014 | 1543 | 0.170 |
Why?
| | Thrombopoietin | 1 | 2021 | 5 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2921 | 0.170 |
Why?
| | Genetic Variation | 2 | 2017 | 996 | 0.170 |
Why?
| | fas Receptor | 2 | 2003 | 91 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 2240 | 0.170 |
Why?
| | B-Lymphocytes | 2 | 2025 | 887 | 0.170 |
Why?
| | Signal Transduction | 7 | 2020 | 5246 | 0.170 |
Why?
| | CD52 Antigen | 1 | 2020 | 3 | 0.160 |
Why?
| | CD3 Complex | 2 | 2001 | 113 | 0.160 |
Why?
| | Carcinoma, Papillary | 1 | 2001 | 83 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 143 | 0.160 |
Why?
| | Cell Survival | 2 | 2014 | 1105 | 0.160 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2022 | 219 | 0.160 |
Why?
| | Receptors, Fc | 1 | 2021 | 54 | 0.160 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2020 | 17 | 0.160 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 122 | 0.160 |
Why?
| | Cell Culture Techniques | 4 | 2011 | 371 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2020 | 173 | 0.150 |
Why?
| | Graft Rejection | 4 | 2021 | 516 | 0.150 |
Why?
| | Neoplasms, Second Primary | 1 | 2001 | 103 | 0.150 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 130 | 0.150 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.150 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6034 | 0.150 |
Why?
| | Cell Self Renewal | 1 | 2019 | 50 | 0.150 |
Why?
| | Arabidopsis Proteins | 1 | 2000 | 78 | 0.150 |
Why?
| | Species Specificity | 1 | 2020 | 543 | 0.150 |
Why?
| | Mice, SCID | 5 | 2021 | 360 | 0.150 |
Why?
| | Blast Crisis | 2 | 2017 | 34 | 0.150 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 23 | 0.150 |
Why?
| | Linkage Disequilibrium | 2 | 2016 | 260 | 0.140 |
Why?
| | Radiotherapy Dosage | 3 | 2016 | 289 | 0.140 |
Why?
| | Busulfan | 1 | 2018 | 15 | 0.140 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2019 | 88 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 585 | 0.140 |
Why?
| | Biomarkers | 6 | 2015 | 4340 | 0.130 |
Why?
| | HLA-DRB1 Chains | 1 | 2018 | 109 | 0.130 |
Why?
| | Pilot Projects | 2 | 2021 | 1888 | 0.130 |
Why?
| | Telomere Homeostasis | 1 | 2017 | 35 | 0.130 |
Why?
| | Prospective Studies | 6 | 2023 | 8123 | 0.130 |
Why?
| | Cell Line | 3 | 2011 | 2814 | 0.130 |
Why?
| | Pediatrics | 2 | 2019 | 1124 | 0.130 |
Why?
| | Epithelial Cell Adhesion Molecule | 2 | 2016 | 10 | 0.130 |
Why?
| | Antibodies, Neoplasm | 1 | 2017 | 34 | 0.130 |
Why?
| | Vidarabine | 4 | 2022 | 32 | 0.130 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 9 | 0.120 |
Why?
| | Dideoxynucleosides | 1 | 2017 | 27 | 0.120 |
Why?
| | Vascularized Composite Allotransplantation | 1 | 2017 | 30 | 0.120 |
Why?
| | Homeostasis | 1 | 2021 | 646 | 0.120 |
Why?
| | Receptors, OX40 | 1 | 2016 | 17 | 0.120 |
Why?
| | Roseolovirus Infections | 1 | 2016 | 8 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2786 | 0.120 |
Why?
| | Thyroid Neoplasms | 1 | 2001 | 380 | 0.120 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 61 | 0.120 |
Why?
| | Gene Expression Profiling | 5 | 2025 | 1792 | 0.120 |
Why?
| | Herpesvirus 6, Human | 1 | 2016 | 14 | 0.120 |
Why?
| | Proportional Hazards Models | 3 | 2015 | 1331 | 0.120 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 24 | 0.120 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2016 | 18 | 0.120 |
Why?
| | Transplantation | 1 | 2016 | 32 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 177 | 0.120 |
Why?
| | Age Factors | 5 | 2021 | 3347 | 0.120 |
Why?
| | Secondary Prevention | 3 | 2014 | 248 | 0.120 |
Why?
| | Whole Body Imaging | 1 | 2016 | 29 | 0.120 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 40 | 0.120 |
Why?
| | Leuprolide | 1 | 2016 | 21 | 0.120 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2015 | 124 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2017 | 175 | 0.120 |
Why?
| | Sociobiology | 1 | 2015 | 2 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2021 | 628 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 416 | 0.110 |
Why?
| | Antibodies, Monoclonal | 3 | 2017 | 1512 | 0.110 |
Why?
| | Immune System Diseases | 1 | 2016 | 43 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 403 | 0.110 |
Why?
| | Interleukin-23 Subunit p19 | 1 | 2015 | 6 | 0.110 |
Why?
| | Mortality | 1 | 2018 | 375 | 0.110 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2016 | 78 | 0.110 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 25 | 0.110 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 22 | 0.110 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 82 | 0.110 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2013 | 150 | 0.110 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 972 | 0.110 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2015 | 21 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 198 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 902 | 0.110 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2014 | 12 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 343 | 0.110 |
Why?
| | Cyclophosphamide | 4 | 2014 | 275 | 0.110 |
Why?
| | Sirolimus | 1 | 2016 | 282 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2016 | 215 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 354 | 0.100 |
Why?
| | Models, Biological | 2 | 2020 | 1761 | 0.100 |
Why?
| | Radiotherapy, Conformal | 1 | 2014 | 75 | 0.100 |
Why?
| | Ovary | 1 | 2016 | 236 | 0.100 |
Why?
| | Mice, Inbred NOD | 4 | 2021 | 598 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4580 | 0.100 |
Why?
| | Radiation Dosage | 1 | 2015 | 193 | 0.100 |
Why?
| | DNA Methylation | 2 | 2016 | 725 | 0.100 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.100 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 21 | 0.100 |
Why?
| | Hypoglycemia | 1 | 2019 | 490 | 0.100 |
Why?
| | Toll-Like Receptor 5 | 1 | 2013 | 18 | 0.100 |
Why?
| | Receptors, Notch | 1 | 2014 | 92 | 0.100 |
Why?
| | Dendritic Cells | 1 | 2017 | 509 | 0.100 |
Why?
| | Luminescent Measurements | 3 | 2002 | 75 | 0.100 |
Why?
| | DNA Repair | 1 | 2016 | 255 | 0.100 |
Why?
| | Phantoms, Imaging | 1 | 2014 | 160 | 0.100 |
Why?
| | Tomography, Spiral Computed | 2 | 2014 | 30 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1995 | 188 | 0.100 |
Why?
| | Risk Assessment | 5 | 2025 | 3712 | 0.100 |
Why?
| | Embryonic Stem Cells | 2 | 2017 | 124 | 0.100 |
Why?
| | Living Donors | 1 | 2015 | 216 | 0.100 |
Why?
| | CTLA-4 Antigen | 1 | 2014 | 105 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2013 | 2791 | 0.100 |
Why?
| | Binding Sites | 1 | 2016 | 1309 | 0.100 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 14 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2015 | 397 | 0.090 |
Why?
| | ADAM Proteins | 1 | 2013 | 65 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2488 | 0.090 |
Why?
| | Pericardial Effusion | 1 | 2013 | 22 | 0.090 |
Why?
| | Receptors, Cytokine | 1 | 2013 | 36 | 0.090 |
Why?
| | Body Size | 1 | 2013 | 91 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2014 | 282 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2019 | 779 | 0.090 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2012 | 40 | 0.090 |
Why?
| | Health Status Indicators | 1 | 2013 | 167 | 0.090 |
Why?
| | Recovery of Function | 1 | 2017 | 725 | 0.090 |
Why?
| | Survivors | 1 | 2016 | 526 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2013 | 180 | 0.090 |
Why?
| | Apolipoprotein C-III | 2 | 2009 | 11 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1242 | 0.090 |
Why?
| | Galectins | 1 | 2012 | 25 | 0.090 |
Why?
| | Feasibility Studies | 3 | 2026 | 1135 | 0.090 |
Why?
| | Machine Learning | 1 | 2018 | 594 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 1 | 2012 | 280 | 0.090 |
Why?
| | Antibody Formation | 1 | 2013 | 290 | 0.090 |
Why?
| | Antigens, Viral | 1 | 2012 | 186 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 115 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 271 | 0.080 |
Why?
| | Ligands | 3 | 2021 | 678 | 0.080 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily D | 1 | 2011 | 2 | 0.080 |
Why?
| | Proteoglycans | 1 | 2011 | 111 | 0.080 |
Why?
| | Antigens, CD20 | 1 | 2011 | 34 | 0.080 |
Why?
| | Leukemia, Experimental | 2 | 2009 | 26 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 213 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 95 | 0.080 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 259 | 0.080 |
Why?
| | Observer Variation | 1 | 2011 | 356 | 0.080 |
Why?
| | Fas Ligand Protein | 2 | 2001 | 61 | 0.080 |
Why?
| | Bone and Bones | 1 | 2013 | 319 | 0.080 |
Why?
| | HL-60 Cells | 3 | 2016 | 29 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2011 | 73 | 0.080 |
Why?
| | Influenza, Human | 1 | 2016 | 640 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 699 | 0.080 |
Why?
| | Umbilical Cord | 1 | 2010 | 92 | 0.080 |
Why?
| | Genotype | 1 | 2015 | 1879 | 0.080 |
Why?
| | Blood Glucose | 1 | 2020 | 2360 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 733 | 0.080 |
Why?
| | Diagnostic Imaging | 2 | 2002 | 340 | 0.070 |
Why?
| | Serologic Tests | 1 | 2009 | 50 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 747 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 2113 | 0.070 |
Why?
| | Graft vs Host Reaction | 1 | 2008 | 2 | 0.070 |
Why?
| | Glycosides | 1 | 2009 | 43 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 303 | 0.070 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 11 | 0.070 |
Why?
| | Thoracic Vertebrae | 1 | 2009 | 90 | 0.070 |
Why?
| | Databases, Factual | 1 | 2014 | 1493 | 0.070 |
Why?
| | Registries | 2 | 2015 | 2400 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2015 | 3017 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 2013 | 563 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 495 | 0.070 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 2 | 2005 | 7 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2134 | 0.060 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2007 | 16 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2007 | 120 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 93 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2020 | 3647 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2006 | 24 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2011 | 2070 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2006 | 75 | 0.060 |
Why?
| | Fibroma, Desmoplastic | 1 | 2006 | 2 | 0.060 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2006 | 12 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 999 | 0.060 |
Why?
| | Central Nervous System | 1 | 2008 | 278 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2025 | 25 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1712 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2018 | 992 | 0.060 |
Why?
| | Liver Diseases | 1 | 2009 | 304 | 0.060 |
Why?
| | Syndrome | 1 | 2026 | 380 | 0.060 |
Why?
| | Meningitis, Viral | 1 | 2005 | 19 | 0.060 |
Why?
| | Killer Cells, Lymphokine-Activated | 2 | 2002 | 12 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1432 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 610 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 277 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2007 | 246 | 0.050 |
Why?
| | Metformin | 1 | 2009 | 328 | 0.050 |
Why?
| | Bariatric Surgery | 1 | 2009 | 250 | 0.050 |
Why?
| | Forkhead Box Protein O1 | 1 | 2025 | 36 | 0.050 |
Why?
| | United States | 4 | 2024 | 16136 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2005 | 633 | 0.050 |
Why?
| | Anemia | 1 | 2006 | 190 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 545 | 0.050 |
Why?
| | Jurkat Cells | 2 | 2017 | 115 | 0.050 |
Why?
| | Trastuzumab | 1 | 2005 | 119 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Inflammation | 1 | 2016 | 2919 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 8391 | 0.050 |
Why?
| | Pharmacovigilance | 1 | 2024 | 25 | 0.050 |
Why?
| | Receptors, Chemokine | 1 | 2024 | 47 | 0.050 |
Why?
| | Mice, Inbred BALB C | 3 | 2002 | 1244 | 0.050 |
Why?
| | Hemoglobins | 1 | 2006 | 384 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 472 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2007 | 584 | 0.050 |
Why?
| | Plasma | 1 | 2005 | 222 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2007 | 399 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 201 | 0.050 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2024 | 74 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 467 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 3125 | 0.050 |
Why?
| | Phenotype | 3 | 2021 | 3206 | 0.050 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 5 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 172 | 0.050 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2023 | 37 | 0.050 |
Why?
| | Enterovirus Infections | 1 | 2005 | 175 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 441 | 0.050 |
Why?
| | Oxidants | 1 | 2003 | 100 | 0.050 |
Why?
| | beta-Thalassemia | 1 | 2003 | 40 | 0.050 |
Why?
| | Physicians | 1 | 2011 | 955 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 517 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 260 | 0.040 |
Why?
| | Pregnancy | 3 | 2010 | 7230 | 0.040 |
Why?
| | Sepsis | 1 | 2009 | 669 | 0.040 |
Why?
| | Liver | 1 | 2011 | 1864 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1041 | 0.040 |
Why?
| | Creatine Kinase | 1 | 2001 | 70 | 0.040 |
Why?
| | Norpregnenes | 1 | 2001 | 4 | 0.040 |
Why?
| | Werner Syndrome | 1 | 2001 | 2 | 0.040 |
Why?
| | Dactinomycin | 1 | 2001 | 24 | 0.040 |
Why?
| | Femoral Neoplasms | 1 | 2001 | 10 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2015 | 3034 | 0.040 |
Why?
| | Perforin | 1 | 2001 | 22 | 0.040 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2001 | 15 | 0.040 |
Why?
| | Thoracotomy | 1 | 2001 | 87 | 0.040 |
Why?
| | Probability | 2 | 2013 | 309 | 0.040 |
Why?
| | Thyroidectomy | 1 | 2001 | 97 | 0.040 |
Why?
| | Hypersensitivity, Immediate | 1 | 2001 | 41 | 0.040 |
Why?
| | Cycloheximide | 1 | 2000 | 42 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 94 | 0.040 |
Why?
| | Vincristine | 1 | 2001 | 148 | 0.040 |
Why?
| | Fatal Outcome | 2 | 2005 | 302 | 0.040 |
Why?
| | Chemokines, CXC | 1 | 2020 | 68 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2001 | 180 | 0.040 |
Why?
| | Fatty Acid Desaturases | 1 | 2000 | 32 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2123 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 366 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2005 | 387 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2418 | 0.040 |
Why?
| | Hospital Costs | 1 | 2021 | 131 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 335 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2001 | 187 | 0.040 |
Why?
| | Methotrexate | 1 | 2001 | 234 | 0.040 |
Why?
| | Placenta Growth Factor | 1 | 2019 | 26 | 0.040 |
Why?
| | Neuropeptides | 1 | 2020 | 76 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 3215 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 429 | 0.040 |
Why?
| | Bleomycin | 1 | 2001 | 255 | 0.040 |
Why?
| | Creatinine | 1 | 2001 | 511 | 0.040 |
Why?
| | Eye Proteins | 1 | 2020 | 93 | 0.040 |
Why?
| | Perioperative Period | 1 | 2019 | 69 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 186 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1143 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 51 | 0.040 |
Why?
| | Microfilament Proteins | 1 | 2020 | 136 | 0.040 |
Why?
| | Cost of Illness | 1 | 2021 | 323 | 0.040 |
Why?
| | Cisplatin | 1 | 2001 | 347 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 200 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 197 | 0.040 |
Why?
| | Doxorubicin | 1 | 2001 | 416 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 51 | 0.030 |
Why?
| | Aging | 1 | 2009 | 1996 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 640 | 0.030 |
Why?
| | Patient Safety | 1 | 2021 | 352 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2020 | 467 | 0.030 |
Why?
| | Protein Phosphatase 2C | 1 | 2017 | 15 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 2017 | 31 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 457 | 0.030 |
Why?
| | Daunorubicin | 1 | 2016 | 25 | 0.030 |
Why?
| | Genes, p53 | 1 | 2017 | 56 | 0.030 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 769 | 0.030 |
Why?
| | Rhodamines | 1 | 2016 | 20 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 432 | 0.030 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 10 | 0.030 |
Why?
| | Radiography, Dual-Energy Scanned Projection | 1 | 2016 | 7 | 0.030 |
Why?
| | Transplants | 1 | 2016 | 36 | 0.030 |
Why?
| | Ovarian Function Tests | 1 | 2016 | 1 | 0.030 |
Why?
| | Premedication | 1 | 2016 | 45 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2016 | 41 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2016 | 23 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2016 | 67 | 0.030 |
Why?
| | Growth Substances | 1 | 2016 | 136 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2016 | 136 | 0.030 |
Why?
| | Myeloproliferative Disorders | 1 | 2016 | 22 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 141 | 0.030 |
Why?
| | HT29 Cells | 1 | 2016 | 37 | 0.030 |
Why?
| | HLA-B Antigens | 1 | 2016 | 59 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1998 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2016 | 91 | 0.030 |
Why?
| | ras Proteins | 1 | 2017 | 148 | 0.030 |
Why?
| | Th1 Cells | 1 | 2016 | 139 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2003 | 1369 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2016 | 116 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 410 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 617 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 143 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 313 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 141 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 174 | 0.030 |
Why?
| | Lung | 1 | 2009 | 4122 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2022 | 0.030 |
Why?
| | Biological Transport | 1 | 2016 | 424 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 15 | 0.030 |
Why?
| | Outpatients | 1 | 2019 | 440 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 304 | 0.030 |
Why?
| | Obesity | 1 | 2009 | 3131 | 0.030 |
Why?
| | Protein Transport | 1 | 2016 | 443 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1177 | 0.030 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.030 |
Why?
| | Macrophages | 1 | 2023 | 1532 | 0.030 |
Why?
| | History, 21st Century | 1 | 2016 | 224 | 0.030 |
Why?
| | Immunotoxins | 1 | 2015 | 51 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2020 | 740 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 193 | 0.030 |
Why?
| | Jaw | 1 | 2014 | 27 | 0.030 |
Why?
| | Follicle Stimulating Hormone | 1 | 2016 | 265 | 0.030 |
Why?
| | History, 20th Century | 1 | 2016 | 330 | 0.030 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 21 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 1995 | 178 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 96 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1574 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 165 | 0.020 |
Why?
| | Bones of Upper Extremity | 1 | 2013 | 4 | 0.020 |
Why?
| | Transduction, Genetic | 2 | 2005 | 129 | 0.020 |
Why?
| | Computer Simulation | 1 | 2018 | 1014 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3416 | 0.020 |
Why?
| | Etoposide | 1 | 2013 | 169 | 0.020 |
Why?
| | Spiro Compounds | 1 | 2013 | 18 | 0.020 |
Why?
| | ADAM17 Protein | 1 | 2013 | 42 | 0.020 |
Why?
| | Pericardiocentesis | 1 | 2013 | 10 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 108 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 221 | 0.020 |
Why?
| | Azacitidine | 1 | 2014 | 168 | 0.020 |
Why?
| | Autoimmunity | 1 | 2019 | 925 | 0.020 |
Why?
| | Immunoglobulin Fragments | 1 | 2012 | 11 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 2009 | 2675 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 372 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2014 | 149 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 371 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 974 | 0.020 |
Why?
| | Kinetics | 1 | 2015 | 1553 | 0.020 |
Why?
| | Receptors, KIR2DL2 | 1 | 2011 | 6 | 0.020 |
Why?
| | Receptors, KIR2DL3 | 1 | 2011 | 9 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2015 | 561 | 0.020 |
Why?
| | Remission, Spontaneous | 1 | 2011 | 39 | 0.020 |
Why?
| | Immunocompetence | 1 | 2011 | 46 | 0.020 |
Why?
| | Spine | 1 | 2013 | 184 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2011 | 12 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 712 | 0.020 |
Why?
| | Piperidines | 1 | 2013 | 225 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2014 | 386 | 0.020 |
Why?
| | Femur | 1 | 2013 | 264 | 0.020 |
Why?
| | Stem Cells | 1 | 2016 | 613 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 403 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2013 | 253 | 0.020 |
Why?
| | ABO Blood-Group System | 1 | 2011 | 56 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 334 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 354 | 0.020 |
Why?
| | Antilymphocyte Serum | 1 | 2010 | 55 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4595 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 736 | 0.020 |
Why?
| | Epitopes | 1 | 2012 | 479 | 0.020 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2010 | 2 | 0.020 |
Why?
| | Seasons | 1 | 2013 | 540 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1849 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 750 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1537 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1224 | 0.020 |
Why?
| | Virus Replication | 1 | 2011 | 526 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1361 | 0.020 |
Why?
| | Cranial Irradiation | 1 | 2008 | 85 | 0.020 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 222 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 391 | 0.020 |
Why?
| | Umbilical Veins | 1 | 2007 | 57 | 0.020 |
Why?
| | Apolipoprotein C-I | 1 | 2006 | 1 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2006 | 6 | 0.020 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.020 |
Why?
| | Granzymes | 1 | 2007 | 51 | 0.020 |
Why?
| | Serum Amyloid A Protein | 1 | 2006 | 32 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3200 | 0.020 |
Why?
| | Minnesota | 1 | 2007 | 167 | 0.010 |
Why?
| | Prealbumin | 1 | 2006 | 37 | 0.010 |
Why?
| | Maternal Age | 1 | 2006 | 129 | 0.010 |
Why?
| | DNA Primers | 1 | 2007 | 487 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2005 | 61 | 0.010 |
Why?
| | Endotoxins | 1 | 2006 | 215 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2008 | 394 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 796 | 0.010 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 419 | 0.010 |
Why?
| | Glycoproteins | 1 | 2006 | 356 | 0.010 |
Why?
| | Universities | 1 | 2007 | 451 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2867 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1077 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2006 | 642 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2005 | 588 | 0.010 |
Why?
| | Cell Membrane | 1 | 2007 | 701 | 0.010 |
Why?
| | Annexin A5 | 1 | 2003 | 23 | 0.010 |
Why?
| | Caspase 8 | 1 | 2003 | 48 | 0.010 |
Why?
| | Lung Transplantation | 1 | 2006 | 326 | 0.010 |
Why?
| | Anion Exchange Protein 1, Erythrocyte | 1 | 2003 | 23 | 0.010 |
Why?
| | Erythropoiesis | 1 | 2003 | 57 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 429 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2009 | 776 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 2003 | 146 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 278 | 0.010 |
Why?
| | Leukemia, B-Cell | 1 | 2002 | 12 | 0.010 |
Why?
| | Caspases | 1 | 2003 | 233 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
| | Luciferases | 1 | 2002 | 153 | 0.010 |
Why?
| | Radiotherapy | 1 | 2002 | 209 | 0.010 |
Why?
| | Creatine | 1 | 2001 | 63 | 0.010 |
Why?
| | Immunoblotting | 1 | 2001 | 294 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2001 | 45 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2001 | 334 | 0.010 |
Why?
| | Hemolysis | 1 | 2003 | 242 | 0.010 |
Why?
| | Blood Proteins | 1 | 2003 | 239 | 0.010 |
Why?
| | Models, Animal | 1 | 2002 | 387 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2001 | 238 | 0.010 |
Why?
| | Luminescent Proteins | 1 | 2002 | 188 | 0.010 |
Why?
| | Forecasting | 1 | 2002 | 388 | 0.010 |
Why?
| | Proteome | 1 | 2005 | 520 | 0.010 |
Why?
| | RNA | 1 | 2007 | 926 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2001 | 534 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2002 | 408 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 310 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1101 | 0.010 |
Why?
| | Cell Death | 1 | 2001 | 379 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2001 | 882 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2002 | 693 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 916 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1412 | 0.010 |
Why?
| | Spleen | 1 | 2001 | 503 | 0.010 |
Why?
| | Phosphorylation | 1 | 2001 | 1724 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1463 | 0.010 |
Why?
|
|
Verneris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|